BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11815960)

  • 1. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine.
    Stein R; Chen S; Reed L; Richel H; Goldenberg DM
    Cancer; 2002 Jan; 94(1):51-61. PubMed ID: 11815960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer.
    Stein R; Juweid M; Zhang CH; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3199s-3206s. PubMed ID: 10541364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy.
    Stein R; Goldenberg DM
    Mol Cancer Ther; 2004 Dec; 3(12):1559-64. PubMed ID: 15634649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
    Stein R; Juweid M; Mattes MJ; Goldenberg DM
    Cancer Biother Radiopharm; 1999 Feb; 14(1):37-47. PubMed ID: 10850286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft.
    Kraeber-Bodéré F; Saï-Maurel C; Campion L; Faivre-Chauvet A; Mirallié E; Chérel M; Supiot S; Barbet J; Chatal JF; Thédrez P
    Mol Cancer Ther; 2002 Feb; 1(4):267-74. PubMed ID: 12467222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.
    Salaun PY; Bodet-Milin C; Frampas E; Oudoux A; Saï-Maurel C; Faivre-Chauvet A; Barbet J; Paris F; Kraeber-Bodéré F
    Cancer; 2010 Feb; 116(4 Suppl):1053-8. PubMed ID: 20127950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F; Bodet-Milin C; Niaudet C; Saï-Maurel C; Moreau A; Faivre-Chauvet A; Thomare P; Deleris G; Estieu-Gionnet K; Bikfalvi A; Barbet J; Paris F
    J Nucl Med; 2010 Apr; 51(4):624-31. PubMed ID: 20351352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
    Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models.
    Sharkey RM; Karacay H; Govindan SV; Goldenberg DM
    Mol Cancer Ther; 2011 Jun; 10(6):1072-81. PubMed ID: 21467164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
    Juweid ME; Hajjar G; Swayne LC; Sharkey RM; Suleiman S; Herskovic T; Pereira M; Rubin AD; Goldenberg DM
    Cancer; 1999 Apr; 85(8):1828-42. PubMed ID: 10223579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine.
    Karacay H; Sharkey RM; Gold DV; Ragland DR; McBride WJ; Rossi EA; Chang CH; Goldenberg DM
    J Nucl Med; 2009 Dec; 50(12):2008-16. PubMed ID: 19949026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influence of combination of low dosage 131I-labeled anti-carcinoembryonic antigen antibody C50 and 5-fluorouracil on tumor growth of colorectal cancer xenografts in nude mice].
    Zheng CX; Zhan WH; Cai SR; He YL; Lin ZJ
    Ai Zheng; 2003 Apr; 22(4):354-7. PubMed ID: 12703987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.
    Blumenthal RD; Taylor A; Osorio L; Ochakovskaya R; Raleigh JA; Papadopoulou M; Bloomer WD; Goldenberg DM
    Int J Cancer; 2001 Nov; 94(4):564-71. PubMed ID: 11745445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy.
    Blumenthal RD; Leone E; Goldenberg DM
    Anticancer Res; 2003; 23(6C):4613-9. PubMed ID: 14981904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.
    Gold DV; Schutsky K; Modrak D; Cardillo TM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3929S-37S. PubMed ID: 14506191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, toxicity and mode of interaction of combination radioimmunotherapy with 5-fluorouracil in colon cancer xenografts.
    Kinuya S; Yokoyama K; Tega H; Hiramatsu T; Konishi S; Watanabe N; Shuke N; Aburano T; Takayama T; Michigishi T; Tonami N
    J Cancer Res Clin Oncol; 1999 Nov; 125(11):630-6. PubMed ID: 10541970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
    O'Donnell RT; DeNardo SJ; Miers LA; Kukis DL; Mirick GR; Kroger LA; DeNardo GL
    Cancer Biother Radiopharm; 1998 Oct; 13(5):351-61. PubMed ID: 10851425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of timing of radioimmunotherapy after granulocyte colony-stimulating factor administration for peripheral blood stem cell harvest.
    Juweid ME; Blumenthal RD; Lew W; Hajjar G; Rubin AD; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3337s-3342s. PubMed ID: 10541383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts.
    Blumenthal RD; Sharkey RM; Natale AM; Kashi R; Wong G; Goldenberg DM
    Cancer Res; 1994 Jan; 54(1):142-51. PubMed ID: 8261435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.